Mobile Health Program for Rural Hypertension
Multilevel Mobile Health Program to Improve Rural Hypertension
2 other identifiers
interventional
334
1 country
1
Brief Summary
Hypertension (HTN) is the leading modifiable cause of cardiovascular disease. Rural individuals experience challenges of the rural health divide: geographic distance from providers, social isolation, limited social resources, and high rates of low health literacy. This study evaluates a home-based blood pressure monitoring (HBPM) program that provides longitudinal health education, empathic guidance, monitoring, and adaptable patient-centered coaching to rural individuals. Participants in this study will be randomized to receive (1) HBPM with the intervention; or (2) the control, consisting of HBPM and a smartphone with a general health application (WebMD).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Sep 2023
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 15, 2022
CompletedFirst Posted
Study publicly available on registry
September 21, 2022
CompletedStudy Start
First participant enrolled
September 4, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 1, 2027
November 19, 2025
November 1, 2025
3.2 years
September 15, 2022
November 16, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in systolic and diastolic blood pressure from baseline to 6 months
Change in home-based systolic and diastolic blood pressure from baseline to 6 months between the intervention and usual care arms.
Baseline, 6 months
Secondary Outcomes (7)
Adherence to antihypertensive medications
Baseline, 6 months
Adherence to antihypertensive medications
Baseline, 12 months
Patient-Reported Outcomes
Baseline, 6 months
Patient-Reported Outcomes
Baseline, 12 months
Self-efficacy for managing medications and treatment
Baseline, 6 months
- +2 more secondary outcomes
Other Outcomes (1)
Change in systolic and diastolic blood pressure from baseline to 6 months, stratified by home-supervised blood pressure at baseline visit.
Baseline, 6 months
Study Arms (2)
Intervention
EXPERIMENTALA smartphone-based, interactive coaching application designed to enhance adherence to home-based blood pressure monitoring, provided guidance on blood pressure management, patient-facing education, and assistance with modifying behaviors associated with poor blood pressure control; connected to a wireless blood pressure cuff for accurate blood pressure measurement and automated storage on a digital platform. All participants in the experimental arm receive a smartphone for the 6-month intervention duration and the home-based blood pressure cuff.
Enhanced usual care
ACTIVE COMPARATORWebMD, a smartphone-based tool for learning about blood pressure and other health conditions. Enhanced usual care participants receive a wireless blood pressure cuff for accurate blood pressure measurement and automated storage on a digital platform. All participants in the experimental arm receive a smartphone for the 6-month intervention duration and the home-based blood pressure cuff.
Interventions
A digital application for providing education and support for home-based blood pressure monitoring.
Device for measuring blood pressure at home with blue tooth connectivity for automated collection.
Eligibility Criteria
You may qualify if:
- History of uncontrolled hypertension, identified from the electronic health record problem list and an average systolic BP 140-199 or diastolic BP 90-119 mm Hg at 2 ambulatory visits, one of which is within 6 months of study entry
- Residence in one of 48 counties categorized as rural by the Center for Rural Pennsylvania;
- English-speaking at level appropriate for informed consent and study participation;
- No plans to relocate from the area within 12 months of enrollment.
You may not qualify if:
- Planned major surgery, cardiovascular or non-cardiovascular;
- Pregnancy or planned pregnancy within 12 months;
- Presence of non-cardiovascular conditions likely to be fatal within 12 months (e.g., cancer);
- Inability to comprehend the study protocol, defined by failing 3 times to answer correctly a set of questions during consent;
- Institutionalized status (e.g., nursing home, incarceration);
- Inability to operate a smartphone or HBPM device due to sensory or neurocognitive deficit.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
September 15, 2022
First Posted
September 21, 2022
Study Start
September 4, 2023
Primary Completion (Estimated)
December 1, 2026
Study Completion (Estimated)
June 1, 2027
Last Updated
November 19, 2025
Record last verified: 2025-11
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
- Time Frame
- The data will be available 12 months following publication of the primary results of this trial.
- Access Criteria
- Researchers who provide a methodologically sound proposal. Proposals should be directed to the Principal Investigator at magnanij@pittt.edu. To gain access, data requestors will need to sign a data access agreement. Data will be provided directly by the study investigators. Costs associated with producing datasets and analysis will be the responsibility of investigators seeking the data.
The study team will share all of the individual participant data collected during the trial, after deidentification.